Literature DB >> 7545695

Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects.

A Hilding1, K Brismar, M Degerblad, M Thorén, K Hall.   

Abstract

To investigate whether previously reported increased levels of insulin-like growth factor-binding protein-1 (IGFBP-1) in GH-deficient patients only reflect decreased levels of insulin or are elevated in relation to insulin, diurnal profiles of IGFBP-1 and insulin were determined in plasma from patients with GH levels below 0.2 microgram/L throughout 24 h (n = 23) and compared to profiles from patients with insulin-dependent diabetes mellitus (IDDM; n = 9) and healthy subjects (n = 12). Samples were drawn using a continuous withdrawal technique at 20-min intervals. Levels of IGF-I were determined in one morning sample. As in healthy subjects, serum IGFBP-1 displayed a diurnal variation in GH-deficient as well as in IDDM patients, with lowest levels in the afternoon and evening and a rise with maximum levels during the night and morning. Fasting and 24-h mean levels of IGFBP-1 were significantly higher in GH-deficient patients [61 +/- 12 (P < 0.01) and 39 +/- 6 micrograms/L (P < 0.01), respectively] and IDDM patients [72 +/- 18 (P < 0.01) and 45 +/- 9 micrograms/L (P < 0.01), respectively] compared to those in healthy subjects (27 +/- 4 and 18 +/- 2 micrograms/L, respectively). Fasting levels of IGFBP-1 correlated to 24-h mean values of IGFBP-1 in all groups separately and in the combined group (r = 0.931; P < 0.001). An inverse relationship was found between IGFBP-1 and insulin in GH-deficient patients, both between 24-h mean values (r = -0.756; P < 0.001) and between fasting values (r = -0.721; P < 0.001). Corresponding values for healthy subjects were r = -0.548; P = 0.065 and r = -0.712; P < 0.01, respectively, whereas in IDDM patients the relationship was nonsignificant. Moreover, in GH-deficient patients, the diurnal mean levels of IGFBP-1 were inversely correlated to IGF-I (r = -0.477; P < 0.05) and body mass index (r = -0.450; P < 0.05). When insulin was taken into account, a tendency for a negative correlation between IGFBP-1 and IGF-I (P = 0.054) remained, whereas the relationship to body mass index disappeared. However, IGFBP-1 levels were elevated in relation to insulin levels in GH-deficient patients compared to healthy subjects (F = 48.7; P < 0.001 and F = 32.5; P < 0.001, diurnal mean values and fasting values, respectively). The majority of the IDDM patients had values in the same range as the GH-deficient patients.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545695     DOI: 10.1210/jcem.80.9.7545695

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study.

Authors:  Robert C Kaplan; Petra Bùzková; Anne R Cappola; Howard D Strickler; Aileen P McGinn; Laina D Mercer; Alice M Arnold; Michael N Pollak; Anne B Newman
Journal:  J Clin Endocrinol Metab       Date:  2012-03-22       Impact factor: 5.958

2.  The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial.

Authors:  A Rafnsson; F Böhm; M Settergren; A Gonon; K Brismar; J Pernow
Journal:  Diabetologia       Date:  2011-12-27       Impact factor: 10.122

3.  Decreased IGF-I bioavailability after ethanol abuse in alcoholics: partial restitution after short-term abstinence.

Authors:  S Röjdmark; K Brismar
Journal:  J Endocrinol Invest       Date:  2001 Jul-Aug       Impact factor: 4.256

4.  Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction.

Authors:  M Wallander; K Brismar; J Ohrvik; L Rydén; A Norhammar
Journal:  Diabetologia       Date:  2006-08-29       Impact factor: 10.122

Review 5.  The glomerular podocyte as a target of growth hormone action: implications for the pathogenesis of diabetic nephropathy.

Authors:  P Anil Kumar; Frank C Brosius; Ram K Menon
Journal:  Curr Diabetes Rev       Date:  2011-01

6.  Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy.

Authors:  Ylva Tiblom Ehrsson; Per M Hellström; Kerstin Brismar; Lena Sharp; Ann Langius-Eklöf; Göran Laurell
Journal:  Support Care Cancer       Date:  2009-10-15       Impact factor: 3.603

7.  Infliximab therapy increases body fat mass in early rheumatoid arthritis independently of changes in disease activity and levels of leptin and adiponectin: a randomised study over 21 months.

Authors:  Inga-Lill Engvall; Birgitta Tengstrand; Kerstin Brismar; Ingiäld Hafström
Journal:  Arthritis Res Ther       Date:  2010-10-21       Impact factor: 5.156

8.  Insulin-like growth factor-binding protein-1 in the prediction and development of type 2 diabetes in middle-aged Swedish men.

Authors:  M S Lewitt; A Hilding; C-G Ostenson; S Efendic; K Brismar; K Hall
Journal:  Diabetologia       Date:  2008-05-22       Impact factor: 10.122

9.  Improved Insulin Sensitivity during Pioglitazone Treatment Is Associated with Changes in IGF-I and Cortisol Secretion in Type 2 Diabetes and Impaired Glucose Tolerance.

Authors:  Lisa Arnetz; Neda Rajamand Ekberg; Charlotte Höybye; Kerstin Brismar; Michael Alvarsson
Journal:  ISRN Endocrinol       Date:  2013-01-15

Review 10.  Utility of free IGF-I measurements.

Authors:  Jan Frystyk
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.